A Microbiome-Inflammation Company
Pioneering Oral immunotherapies for long-term disease modification and enhanced quality of life for many patients.
Type 1 Diabetes: ImmunoBiota’s Lead Indication
No current therapies effectively target the root causes of Type 1 Diabetes (T1D).
Underlying Causes of T1D
- Altered gut microbial metabolites
- Exacerbated Autoimmune Responses
- Tissue Inflammation
- Microbiome dysfunction
- Beta-cell destruction
ImmunoBiota
Therapeutics
Our studies have shown that our therapeutic candidate delivers potent anti-inflammatory metabolites directly in the gut to reverse Type 1 Diabetes without immunosuppression.
Clinically Validated in Adults and Children with Type 1 Diabetes and Hypertension
Microbiome science for you
Transformative Impact
ImmunoBiota is pioneering a unique oral therapy aimed at delaying, halting, or reversing Type 1 Diabetes in individuals of all ages and stages, including those at high risk and established patients.
By restoring immune and microbiome balance, it may lead to long-term remission and better metabolic control.
Unmatched Differentiation
Safety Profile
The safest and most effective delivery method to restore and sustain optimal anti-inflammatory SCFA levels in both the colon and circulation.
Robust Data
Novel oral therapeutic. It works under the controlled action of the gut microbiota.
Scientifically and Clinical Proven
Clinical trial-backed safety and therapeutic efficacy with >90% patient adherence. No immunosuppression. IBT tx is not approved and undergoing clinical studies.
Unique value Proposition
Unique patented metabolite-targeted technology indicated to preserve and regenerate endogenous insulin secretion.